Health Care & Life Sciences » Pharmaceuticals | NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
5,335.00
7,152.00
2,502.00
14.00
27.00
5
Cost of Goods Sold (COGS) incl. D&A
22,929.00
52,749.00
52,909.00
38,564.00
32,501.00
32,582
Gross Income
17,594.00
45,597.00
50,407.00
38,550.00
32,474.00
32,577
EBIT
23,706.00
44,476.00
62,768.00
50,551.00
60,400.00
72,174
Unusual Expense
-
-
28,135.00
21,135.00
-
2,858
Non Operating Income/Expense
1,157.00
1,322.00
36.00
206.00
11,266.00
1,538
Pretax Income
22,126.00
44,673.00
90,801.00
71,873.00
71,659.00
73,494
Equity in Affiliates
-
-
-
28.00
56.00
-
Consolidated Net Income
22,126.00
44,673.00
90,801.00
71,845.00
71,603.00
73,494
Net Income
22,331.00
42,549.00
90,119.00
70,240.00
66,728.00
68,373
Net Income After Extraordinaries
22,331.00
42,549.00
90,119.00
70,240.00
66,728.00
68,373
Net Income Available to Common
22,331.00
42,549.00
90,119.00
70,240.00
66,728.00
68,373
EPS (Basic)
0.87
1.22
2.35
1.49
1.19
0.79
Basic Shares Outstanding
25,827.50
34,836.10
38,378.80
46,918.30
56,150.30
86,771.20
EPS (Diluted)
0.86
1.22
2.35
1.50
1.19
0.79
Diluted Shares Outstanding
25,827.50
34,836.10
38,378.80
46,918.30
56,150.30
86,771.20
EBITDA
23,559.00
44,035.00
61,568.00
49,430.00
58,805.00
71,936
Other Operating Expense
6,112.00
1,121.00
12,361.00
12,001.00
27,926.00
-
Non-Operating Interest Income
423.00
1,125.00
66.00
19.00
7.00
-
Minority Interest Expense
205.00
2,124.00
682.00
1,605.00
4,875.00
5,121

About NeuroVive Pharmaceutical AB

View Profile
Address
Medicon Village
Lund SN 223 81
Sweden
Employees -
Website http://www.neurovive.com
Updated 07/08/2019
NeuroVive Pharmaceutical AB engages in the research and development of pharmaceuticals that protect mitochondria from death post acute traumatic injury. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden. .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.